Last checked at 
(Alliance News) - AstraZeneca PLC on Sunday reported ACE-LY-004 phase II trial results, showing efficacy and safety profile of Calquence in mantle cell lymphoma.
The Cambridge, England-based biopharmaceutical company said patients with relapsed or refractory mantle cell lymphoma remained progression free for a median of 22 months, with median overall survival not yet reached at three years of follow-up.
The safety and tolerability profile remained consistent.
"Mantle cell lymphoma is an aggressive, difficult-to-treat blood cancer that is typically diagnosed at an advanced stage and often becomes resistant to treatment. This data shows that patients treated with acalabrutinib experienced deep responses over time, while the safety profile remained largely the same," said Michael Wang, principal investigator of the ACE-LY-004 phase II trial.
"These results add to the mounting evidence that Calquence can provide sustained responses in patients over more than three years," said Jose Baselga, executive vice president of Oncology Research & Development at AstraZeneca.
The results of the study served as the basis for the first US Food & Drug Administration approval of Calquence in adult patients with mantle cell lymphoma who have received at least one prior therapy. Calquence is approved for this indication in many other countries.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
